Subscribe
winui
Winui / Shutterstock.com
9 July 2020AmericasJonathan Harris, Ian Lodovice, and Nisan Zaghi

Five core IP legal principles in life sciences

Comprehensive and effective IP due diligence in life science transactions is essential. This is especially true of emerging and growth life science companies, where a single asset protected by strong IP can command hundreds of millions of dollars.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biogen takes Creative Biolabs to court over antibody
19 March 2020   Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.
Big Pharma
Biogen fights off Mylan’s Tecfidera patent challenge
6 February 2020   US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

The Quintara decision: Defining trade secrets in federal cases
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Trump’s march-in rights threat: Why pharma is rethinking collaborations
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?